ClinicalTrials.gg
Active, not recruitingNCT04994509PURPOSE 1Updated Oct 16, 2026Results posted

Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV Infection

A Phase 3 interventional study of Oral Lenacapavir (LEN) and Subcutaneous (SC) Lenacapavir (LEN) in Pre-Exposure Prophylaxis of HIV Infection, sponsored by Gilead Sciences. Active, not recruiting at 28 sites in 2 countries. Open to female participants aged 16 Years to 25 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
5,368
Allocation
Randomized
Ages
16 Years to 25 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 65 studies testing emtricitabine in HIV Infections — 4 open to participants now, 8 under way, 4 of them phase 3. Emtricitabine · HIV Infections.

Enrollment
Largest of 63
5,368 · median 100
Started
2021
with 1 other
Phase 3
17 of 65
1 open now
Registered
57th of 65
by date
Lead sponsor
14 of 65
Gilead Sciences

Among the 65 studies testing emtricitabine in HIV Infections, this one has the largest enrollment of the 63 interventional ones that give a count, is one of 2 that started in 2021, is one of 17 in phase 3, and was the 57th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

4 of the 65 studies testing emtricitabine in HIV Infections are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About emtricitabine

Emtricitabine: first FDA approval 2003 (EMTRIVA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 16 Years to 25 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies testing emtricitabine in HIV Infections, or all of them as a file.
02

Study summary

The goal of this study is to evaluate the efficacy of the study drugs, lenacapavir (LEN) and emtricitabine/tenofovir alafenamide (F/TAF) in preventing HIV infection, in adolescent girls and young women (AGYW).

The primary objective of this study is to evaluate the efficacy of LEN and F/TAF for HIV-1 PrEP in AGYW at risk of HIV-1 infection.

03

Conditions studied

  • Pre-Exposure Prophylaxis of HIV Infection

Browse trials for

04

Who can participate

Ages eligible
16 Years to 25 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Incidence Phase

    • -1 status unknown at initial screening and no prior human immunodeficiency virus (HIV)-1 testing within the last 3 months.
    • Sexually active (has had > 1 vaginal intercourse within the last 3 months) with cisgender male individuals (CGM).
  • Randomized Phase

    • Negative fourth generation HIV-1 antibody (Ab)/antigen (Ag) test confirmed with central HIV-1 testing.
    • Estimated (GFR) ≥ 60 mL/min at screening.
    • Body weight ≥ 35 kg.

Key Exclusion Criteria:

  • Prior receipt of an HIV vaccine.
  • Prior use of any long-acting systemic HIV pre-exposure prophylaxis (PrEP) or prior HIV postexposure prophylaxis (PEP) in the past 12 weeks.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
5,368 participants (actual)

Study arms

  • Experimental
    Randomized Blinded Phase: Lenacapavir

    Participants will receive lenacapavir (LEN) 927 mg injection, every 26 weeks starting on Day 1 for up to approximately 52 weeks. Participants will also receive loading dose of LEN 600 mg, tablet, once daily on Day 1 and Day 2. Participants will receive placebo to match (PTM) emtricitabine/tenofovir disoproxil fumarate (F/TDF) or PTM emtricitabine/tenofovir alafenamide (F/TAF), once daily, up to approximately 52 weeks.

    Drug: Oral Lenacapavir (LEN) · Drug: Subcutaneous (SC) Lenacapavir (LEN) · Drug: PTM F/TAF · Drug: PTM F/TDF

  • Experimental
    Randomized Blinded Phase: F/TAF

    Participants will receive F/TAF, once daily up to approximately 52 weeks. Participants will also receive PTM LEN injection, every 26 weeks, starting on Day 1 up to approximately 52 weeks. Participants will receive PTM LEN tablet, once daily on Day 1 and Day 2.

    Drug: F/TAF · Drug: Placebo SC LEN · Drug: PTM Oral LEN

  • Experimental
    Randomized Blinded Phase: F/TDF

    Participants will receive F/TDF, once daily up to approximately 52 weeks. Participants will also receive PTM LEN injection, every 26 weeks starting on Day 1 up to approximately 52 weeks. Participants will receive PTM LEN tablet, once daily on Day 1 and Day 2.

    Drug: F/TDF · Drug: Placebo SC LEN · Drug: PTM Oral LEN

  • Experimental
    LEN Open-Label Extension (OLE) Phase

    After completion of the Blinded phase, participants will be offered entry into the LEN OLE Phase. Participants randomized to LEN will continue to receive LEN 927 mg injection, every 26 weeks until LEN becomes available or the sponsor elects to discontinue the study, whichever occurs first. Participants randomized to F/TAF or F/TDF will receive LEN 927 mg injection on OLE Day 1, Week 26, and every 26 weeks thereafter. Participants will also receive LEN 600 mg tablet on OLE Days 1 and 2.

    Drug: Oral Lenacapavir (LEN) · Drug: Subcutaneous (SC) Lenacapavir (LEN)

  • Experimental
    Pharmacokinetic (PK) Tail Coverage Phase

    Participants who prematurely discontinue study drug in the randomized blinded phase will transition into the PK Tail Coverage phase. Participants will receive F/TDF, once daily, for 78 weeks beginning 26 weeks after the last LEN injection.

    Drug: F/TDF

Interventions

  • Tablets administered orally without regard to food

    Also known as: GS-6207

  • Administered via SC injections

    Also known as: GS-6207, Yeztugo®, Yeytuo®

  • DrugF/TAF

    Drug pages: Emtricitabine · Tenofovir alafenamide

    Tablets administered orally

    Also known as: Descovy®

  • DrugF/TDF

    Tablets administered orally

    Also known as: Truvada®

  • DrugPlacebo SC LEN

    Administered via SC injections

  • DrugPTM Oral LEN

    Tablets administered orally

  • DrugPTM F/TAF

    Tablets administered orally

  • DrugPTM F/TDF

    Tablets administered orally

06

What researchers measure

Primary outcomes

  1. Incidence Phase: Recent Infection Testing Algorithm (RITA) Estimate of the Background Human Immunodeficiency-1 Virus Infection Incidence Rate (bHIV) Per 100 Person Years (PY)

    bHIV per 100 PY in the Incidence Phase was calculated using RITA. The RITA incorporated HIV-1 testing results and recency assay testing results to estimate the bHIV. Recency assay testing was performed for participants in the All Screened Set found to have HIV-1 infection at the Incidence Phase Screening Visit as defined below. Participants were considered to have recent HIV-1 infection if the normalized optical density (ODn) was below 1.5 threshold using the Sedia limiting antigen avidity enzyme immunoassay (LAg-EIA) and the HIV-1 RNA (viral load) was \> 75 copies/mL of blood. HIV-1 infection was defined as participants having at least one of the following central lab results at the Incidence Phase screening visit: * Positive HIV-1/2 differentiation Ab, OR * Positive HIV-1 ribonucleic acid (RNA) qualitative test, OR * HIV-1 RNA quantitative test ≥200 copies/mL.

    Time frame: Incidence Phase Screening Visit (Day 1)

  2. Randomized Blinded Phase: HIV-1 Incidence Reported Per 100 PY for LEN and F/TAF Compared to Participants in All Screened Set

    HIV-1 incidence per 100 PY for LEN and F/TAF was calculated as the number of participants who acquired HIV-1 divided by the total of a) for participants not diagnosed with HIV-1, sum of all duration of follow-up time in years, while at risk of HIV-1 infection (where a year is 365.25 days) and b) for participants diagnosed with HIV-1, sum of all duration of follow-up time up to confirmed HIV-1 diagnoses. HIV-1 diagnosis was determined by an HIV adjudication committee who reviewed potential HIV-1 infection events in the randomized participants. The committee, in a blinded, consistent, and unbiased manner, determined whether HIV test results confirmed HIV-1 infection and determined the date of diagnosis for each case, defined as the date of the earliest study visit with evidence of HIV infection considering both prospective HIV testing and back-testing of archived samples. bHIV incidence per 100 PY in All Screened Set was estimated as described in outcome measure#1.

    Time frame: When at least 50% of the participants completed 52 weeks of follow-up after randomization or permanently discontinued from the study (maximum 143 weeks)

Secondary outcomes

  1. Randomized Blinded Phase: HIV-1 Incidence Reported Per 100 PY for LEN, F/TAF and F/TDF

    HIV-1 incidence per 100 PY was calculated as the number of participants who acquired HIV-1 divided by the total of a) for participants not diagnosed with HIV-1, sum of all duration of follow-up time in years, while at risk of HIV-1 infection (where a year is 365.25 days) and b) for participants diagnosed with HIV-1, sum of all duration of follow-up time up to confirmed HIV-1 diagnoses. HIV-1 diagnosis was determined by an HIV adjudication committee who reviewed potential HIV-1 infection events in the randomized participants. The committee, in a blinded, consistent, and unbiased manner, determined whether HIV test results confirmed HIV-1 infection and determined the date of diagnosis for each case, defined as the date of the earliest study visit with evidence of HIV infection considering both prospective HIV testing and back-testing of archived samples.

    Time frame: When at least 50% of the participants completed 52 weeks of follow-up after randomization or permanently discontinued from the study (maximum 143 weeks)

  2. Randomized Blinded Phase: HIV-1 Incidence Among Participants Adherent to LEN

    A participant was defined as adherent to LEN if they have received all per-protocol administrations of LEN within 28 weeks since the previous administration. The incidence of HIV-1 infection per 100 PY calculation is defined in outcome measure #2.

    Time frame: When at least 50% of the participants completed 52 weeks of follow-up after randomization or permanently discontinued from the study (maximum 143 weeks)

  3. Randomized Blinded Phase: Percentage of Participants Adherent to F/TAF in HIV-1 Diagnosed Participants and Their Matched Controls

    A participant's adherence to F/TAF was measured by tenofovir diphosphate (TFV-DP) in dried blood spot (DBS) samples, where \<450 fmol/punch associates with an adherence of \<2 days per week. The data is reported in two categories: low adherence (\<2 days per week) and not low adherence (\>= 2 days per week).

    Time frame: When at least 50% of the participants completed 52 weeks of follow-up after randomization or permanently discontinued from the study (maximum 143 weeks)

  4. Randomized Blinded Phase: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)

    TEAEs were defined as 1 or both of the following: * Any adverse events (AEs) leading to premature discontinuation of study drug, or * Any AEs with an onset date on or after the study drug start date and no later than the last exposure date after permanent discontinuation of the study drug. * An AE was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily had a causal relationship with the treatment. The severity of the AEs was graded using the division of AIDS (DAIDS) toxicity grading scale version 2.1. The DAIDS grading table provides an AE severity grading scale ranging from grades 1 to 5 with descriptions for each AE based on the following general guidelines : Grade 1 indicates a mild event, Grade 2 indicates a moderate event, Grade 3 indicates a severe event, Grade 4 indicates a potentially life-threatening event, Grade 5 indicates death. Percentages were rounded off.

    Time frame: Up to 165 weeks

  5. Randomized Blinded Phase: Percentage of Participants With Grade 3 or Higher Laboratory Abnormalities

    Treatment-emergent laboratory abnormalities were defined as values that increased at least 1 toxicity grade from baseline at any post-baseline visit, up to and including the last exposure date for participants who permanently discontinued study drug, or the last available date in the database snapshot for participants who were still on treatment at the time of an analysis. The DAIDS Toxicity Grading Scale, Version 2.1 was used to assign toxicity grades (0 to 4) to laboratory results for analysis. Grade 0 included all values that do not meet the criteria for an abnormality of at least Grade 1. Grade 1 mild, Grade 2 moderate, Grade 3 severe, and Grade 4 potentially life-threatening. Percentages were rounded off.

    Time frame: Up to 165 weeks

07

Results

Posted Jun 19, 2025
Limitations and caveats
Due to data monitoring committee recommendation to stop the study early if the prespecified evaluation criteria were met, this is the date by when at least 50% of the participants were followed up for at least 52 weeks in the study.

Participant flow

8402 participants were screened. Out of 8402, 8094 participants had at least 1 non-missing HIV-1 diagnosis based on HIV test results from a central laboratory. Therefore, 8094 participants were considered for screening in the Incidence Phase and were included in the All Screened Set.

Randomized Blinded Phase
Participant flow — Randomized Blinded Phase
MilestoneRandomized Blinded Phase: LenacapavirRandomized Blinded Phase: F/TAFRandomized Blinded Phase: F/TDFOpen-Label Extension (OLE) Phase: LENOLE Phase: F/TAFOLE Phase: F/TDF
Started214821471073000
Randomized phase safety analysis set214021351070000
Completed19001853898000
Not completed248294175000
Withdrew: Withdrew consent10810964000
Withdrew: Lost to follow-up10010066000
Withdrew: Hiv-1 infection44521000
Withdrew: Investigator's discretion141116000
Withdrew: Randomized but never treated10103000
Withdrew: Pregnancy583000
Withdrew: Death061000
Withdrew: Adverse event310000
Withdrew: Non-compliance with study drug241000
Withdrew: Withdrew assent100000
Withdrew: Protocol violation100000
OLE Phase (LEN OLE and PK Tail Phases)
Participant flow — OLE Phase (LEN OLE and PK Tail Phases)
MilestoneRandomized Blinded Phase: LenacapavirRandomized Blinded Phase: F/TAFRandomized Blinded Phase: F/TDFOpen-Label Extension (OLE) Phase: LENOLE Phase: F/TAFOLE Phase: F/TDF
Started00018931768866
Completed000000
Not completed00018931768866
Withdrew: Still on study00018931768866

Outcome measures

PrimaryIncidence Phase: Recent Infection Testing Algorithm (RITA) Estimate of the Background Human Immunodeficiency-1 Virus Infection Incidence Rate (bHIV) Per 100 Person Years (PY)

bHIV per 100 PY in the Incidence Phase was calculated using RITA. The RITA incorporated HIV-1 testing results and recency assay testing results to estimate the bHIV. Recency assay testing was performed for participants in the All Screened Set found to have HIV-1 infection at the Incidence Phase Screening Visit as defined below. Participants were considered to have recent HIV-1 infection if the normalized optical density (ODn) was below 1.5 threshold using the Sedia limiting antigen avidity enzyme immunoassay (LAg-EIA) and the HIV-1 RNA (viral load) was \> 75 copies/mL of blood. HIV-1 infection was defined as participants having at least one of the following central lab results at the Incidence Phase screening visit: * Positive HIV-1/2 differentiation Ab, OR * Positive HIV-1 ribonucleic acid (RNA) qualitative test, OR * HIV-1 RNA quantitative test ≥200 copies/mL.

Time frame:
Incidence Phase Screening Visit (Day 1)
Reported as:
Number · HIV-1 events per 100 person-years
Incidence Phase: Recent Infection Testing Algorithm (RITA) Estimate of the Background Human Immunodeficiency-1 Virus Infection Incidence Rate (bHIV) Per 100 Person Years (PY)
HIV-1 events per 100 person-yearsParticipants Screened for HIV-1 in Incidence Phase
Incidence Phase: Recent Infection Testing Algorithm (RITA) Estimate of the Background Human Immunodeficiency-1 Virus Infection Incidence Rate (bHIV) Per 100 Person Years (PY)2.407 (1.815 to 3.191)
PrimaryRandomized Blinded Phase: HIV-1 Incidence Reported Per 100 PY for LEN and F/TAF Compared to Participants in All Screened Set

HIV-1 incidence per 100 PY for LEN and F/TAF was calculated as the number of participants who acquired HIV-1 divided by the total of a) for participants not diagnosed with HIV-1, sum of all duration of follow-up time in years, while at risk of HIV-1 infection (where a year is 365.25 days) and b) for participants diagnosed with HIV-1, sum of all duration of follow-up time up to confirmed HIV-1 diagnoses. HIV-1 diagnosis was determined by an HIV adjudication committee who reviewed potential HIV-1 infection events in the randomized participants. The committee, in a blinded, consistent, and unbiased manner, determined whether HIV test results confirmed HIV-1 infection and determined the date of diagnosis for each case, defined as the date of the earliest study visit with evidence of HIV infection considering both prospective HIV testing and back-testing of archived samples. bHIV incidence per 100 PY in All Screened Set was estimated as described in outcome measure#1.

Time frame:
When at least 50% of the participants completed 52 weeks of follow-up after randomization or permanently discontinued from the study (maximum 143 weeks)
Reported as:
Number · HIV-1 events per 100 person-years
Randomized Blinded Phase: HIV-1 Incidence Reported Per 100 PY for LEN and F/TAF Compared to Participants in All Screened Set
HIV-1 events per 100 person-yearsRandomized Blinded Phase: LenacapavirRandomized Blinded Phase: F/TAFIncidence Phase: All Screened Participants With Non-missing HIV-1 Diagnosis
Randomized Blinded Phase: HIV-1 Incidence Reported Per 100 PY for LEN and F/TAF Compared to Participants in All Screened Set0.000 (0.000 to 0.190)2.018 (1.435 to 2.759)2.407 (1.815 to 3.191)
Statistical analysis
  • Randomized Blinded Phase: Lenacapavir vs Incidence Phase: All Screened Participants With Non-missing HIV-1 Diagnosis · Likelihood ratio test · p = <0.0001 (p-value for rate ratio vs bHIV is from likelihood ratio test.) · Rate ratio: 0.000 · 95% CI 0.000 to 0.042Confidence Interval (CI) for rate ratio vs bHIV is from a likelihood-based method.
  • Randomized Blinded Phase: Lenacapavir vs Incidence Phase: All Screened Participants With Non-missing HIV-1 Diagnosis · Likelihood ratio test · p = <0.0001 (p-value for rate ratio vs bHIV is from likelihood ratio test.) · Rate ratio: 0.000 · 95% CI 0.000 to 0.042CI for rate ratio vs bHIV is based on a likelihood-based method.
  • Randomized Blinded Phase: F/TAF vs Incidence Phase: All Screened Participants With Non-missing HIV-1 Diagnosis · Wald test · p = 0.20697 (p-value for rate ratio vs bHIV is from Wald test.) · Rate ratio: 0.839 · 95% CI 0.550 to 1.279CI for rate ratio vs bHIV is based on the delta method.
  • Randomized Blinded Phase: F/TAF vs Incidence Phase: All Screened Participants With Non-missing HIV-1 Diagnosis · Wald test · p = 0.58674 (p-value for rate ratio vs bHIV is from Wald test.) · Rate ratio: 0.839 · 95% CI 0.550 to 1.279CI for rate ratio vs bHIV is based on the delta method.
SecondaryRandomized Blinded Phase: HIV-1 Incidence Reported Per 100 PY for LEN, F/TAF and F/TDF

HIV-1 incidence per 100 PY was calculated as the number of participants who acquired HIV-1 divided by the total of a) for participants not diagnosed with HIV-1, sum of all duration of follow-up time in years, while at risk of HIV-1 infection (where a year is 365.25 days) and b) for participants diagnosed with HIV-1, sum of all duration of follow-up time up to confirmed HIV-1 diagnoses. HIV-1 diagnosis was determined by an HIV adjudication committee who reviewed potential HIV-1 infection events in the randomized participants. The committee, in a blinded, consistent, and unbiased manner, determined whether HIV test results confirmed HIV-1 infection and determined the date of diagnosis for each case, defined as the date of the earliest study visit with evidence of HIV infection considering both prospective HIV testing and back-testing of archived samples.

Time frame:
When at least 50% of the participants completed 52 weeks of follow-up after randomization or permanently discontinued from the study (maximum 143 weeks)
Reported as:
Number · HIV-1 events per 100 person-years
Randomized Blinded Phase: HIV-1 Incidence Reported Per 100 PY for LEN, F/TAF and F/TDF
HIV-1 events per 100 person-yearsRandomized Blinded Phase: LenacapavirRandomized Blinded Phase: F/TAFRandomized Blinded Phase: F/TDF
Randomized Blinded Phase: HIV-1 Incidence Reported Per 100 PY for LEN, F/TAF and F/TDF0.000 (0.000 to 0.190)2.018 (1.435 to 2.759)1.685 (0.963 to 2.737)
Statistical analysis
  • Randomized Blinded Phase: Lenacapavir vs Randomized Blinded Phase: F/TDF · Poisson model · p = < 0.0001 (p-value for rate ratio vs F/TDF is from an exact conditional Poisson model.) · Rate ratio: 0.000 · 95% CI 0.000 to 0.101CI is from an exact conditional Poisson model.
  • Randomized Blinded Phase: F/TAF vs Randomized Blinded Phase: F/TDF · Poisson model · p = 0.72820 (p-value for rate ratio vs F/TDF is from a Poisson model.) · Rate ratio: 1.198 · 95% CI 0.669 to 2.143CI is from a Poisson model.
  • Randomized Blinded Phase: Lenacapavir vs Randomized Blinded Phase: F/TDF · Hybrid approach · p = <0.0001 (p-value for rate difference vs F/TDF is based on a hybrid approach.) · Rate difference: -1.685 · 95% CI -2.737 to -0.939Exact CI is based on a hybrid approach.
  • Randomized Blinded Phase: F/TAF vs Randomized Blinded Phase: F/TDF · Hybrid approach · p = 0.20900 (p-value for rate difference vs F/TDF is based on a hybrid approach.) · Rate difference: 0.333 · 95% CI -0.869 to 1.367Exact CI is based on a hybrid approach.
SecondaryRandomized Blinded Phase: HIV-1 Incidence Among Participants Adherent to LEN

A participant was defined as adherent to LEN if they have received all per-protocol administrations of LEN within 28 weeks since the previous administration. The incidence of HIV-1 infection per 100 PY calculation is defined in outcome measure #2.

Time frame:
When at least 50% of the participants completed 52 weeks of follow-up after randomization or permanently discontinued from the study (maximum 143 weeks)
Reported as:
Number · HIV-1 events per 100 person-years
Randomized Blinded Phase: HIV-1 Incidence Among Participants Adherent to LEN
HIV-1 events per 100 person-yearsRandomized Blinded Phase: Lenacapavir
Randomized Blinded Phase: HIV-1 Incidence Among Participants Adherent to LEN0.000 (0.000 to 0.214)
SecondaryRandomized Blinded Phase: Percentage of Participants Adherent to F/TAF in HIV-1 Diagnosed Participants and Their Matched Controls

A participant's adherence to F/TAF was measured by tenofovir diphosphate (TFV-DP) in dried blood spot (DBS) samples, where \<450 fmol/punch associates with an adherence of \<2 days per week. The data is reported in two categories: low adherence (\<2 days per week) and not low adherence (\>= 2 days per week).

Time frame:
When at least 50% of the participants completed 52 weeks of follow-up after randomization or permanently discontinued from the study (maximum 143 weeks)
Reported as:
Number · percentage of participants
Randomized Blinded Phase: Percentage of Participants Adherent to F/TAF in HIV-1 Diagnosed Participants and Their Matched Controls
percentage of participantsRandomized Blinded Phase: F/TAF (Participants With HIV-1 Diagnosis)Randomized Blinded Phase: F/TAF (Matched Controls - Participants With No HIV-1 Diagnosis)
Low (< 2 days/Week)91.965.9
Not Low (>= 2 days/Week)8.134.1
Statistical analysis
  • Randomized Blinded Phase: F/TAF (Participants With HIV-1 Diagnosis) vs Randomized Blinded Phase: F/TAF (Matched Controls - Participants With No HIV-1 Diagnosis) · ExactConditionalLogisticRegressionModel · p = 0.0006 (p-value is from exact conditional logistic regression model.) · Exact odds ratio: 9.00 · 95% CI 2.06 to 83.36Exact odds ratio and and CI are from exact conditional logistic regression model.
SecondaryRandomized Blinded Phase: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)

TEAEs were defined as 1 or both of the following: * Any adverse events (AEs) leading to premature discontinuation of study drug, or * Any AEs with an onset date on or after the study drug start date and no later than the last exposure date after permanent discontinuation of the study drug. * An AE was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily had a causal relationship with the treatment. The severity of the AEs was graded using the division of AIDS (DAIDS) toxicity grading scale version 2.1. The DAIDS grading table provides an AE severity grading scale ranging from grades 1 to 5 with descriptions for each AE based on the following general guidelines : Grade 1 indicates a mild event, Grade 2 indicates a moderate event, Grade 3 indicates a severe event, Grade 4 indicates a potentially life-threatening event, Grade 5 indicates death. Percentages were rounded off.

Time frame:
Up to 165 weeks
Reported as:
Number · percentage of participants
Randomized Blinded Phase: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)
percentage of participantsRandomized Blinded Phase: LenacapavirRandomized Blinded Phase: F/TAFRandomized Blinded Phase: F/TDF
Randomized Blinded Phase: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)90.886.685.3
SecondaryRandomized Blinded Phase: Percentage of Participants With Grade 3 or Higher Laboratory Abnormalities

Treatment-emergent laboratory abnormalities were defined as values that increased at least 1 toxicity grade from baseline at any post-baseline visit, up to and including the last exposure date for participants who permanently discontinued study drug, or the last available date in the database snapshot for participants who were still on treatment at the time of an analysis. The DAIDS Toxicity Grading Scale, Version 2.1 was used to assign toxicity grades (0 to 4) to laboratory results for analysis. Grade 0 included all values that do not meet the criteria for an abnormality of at least Grade 1. Grade 1 mild, Grade 2 moderate, Grade 3 severe, and Grade 4 potentially life-threatening. Percentages were rounded off.

Time frame:
Up to 165 weeks
Reported as:
Number · percentage of participants
Randomized Blinded Phase: Percentage of Participants With Grade 3 or Higher Laboratory Abnormalities
percentage of participantsRandomized Blinded Phase: LenacapavirRandomized Blinded Phase: F/TAFRandomized Blinded Phase: F/TDF
Randomized Blinded Phase: Percentage of Participants With Grade 3 or Higher Laboratory Abnormalities7.26.37.4

Adverse events

Collected over All-Cause Mortality: Up to 165 Weeks; Adverse Events: Up to 165 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Randomized Blinded Phase: Lenacapavir0/2,148 (0%)81/2,140 (3.8%)1,827/2,140 (85.4%)
Randomized Blinded Phase: F/TAF7/2,147 (0.3%)105/2,135 (4.9%)1,646/2,135 (77.1%)
Randomized Blinded Phase: F/TDF1/1,073 (0.1%)44/1,070 (4.1%)794/1,070 (74.2%)
Most frequent serious events
Showing 10 of 113
Most frequent serious events
EventRandomized Blinded Phase: LenacapavirRandomized Blinded Phase: F/TAFRandomized Blinded Phase: F/TDF
Abortion spontaneousPregnancy, puerperium and perinatal conditions18/214030/213512/1070
AsthmaRespiratory, thoracic and mediastinal disorders0/21401/21354/1070
MalariaInfections and infestations3/21405/21350/1070
Intentional self-injuryPsychiatric disorders3/21404/21351/1070
Suicide attemptPsychiatric disorders2/21404/21350/1070
GastritisGastrointestinal disorders0/21401/21352/1070
Humerus fractureInjury, poisoning and procedural complications0/21400/21352/1070
Lower limb fractureInjury, poisoning and procedural complications0/21400/21352/1070
MigraineNervous system disorders0/21400/21352/1070
Foetal distress syndromePregnancy, puerperium and perinatal conditions4/21403/21351/1070
Most frequent other events
Showing 10 of 15
Most frequent other events
EventRandomized Blinded Phase: LenacapavirRandomized Blinded Phase: F/TAFRandomized Blinded Phase: F/TDF
Injection site noduleGeneral disorders1415/2140376/2135202/1070
Injection site painGeneral disorders731/2140583/2135264/1070
HeadacheNervous system disorders327/2140373/2135165/1070
Genitourinary chlamydia infectionInfections and infestations352/2140365/2135148/1070
Urinary tract infectionInfections and infestations344/2140338/2135181/1070
Upper respiratory tract infectionInfections and infestations344/2140335/2135146/1070
NauseaGastrointestinal disorders164/2140249/2135146/1070
VomitingGastrointestinal disorders144/2140253/2135115/1070
Vaginal dischargeReproductive system and breast disorders203/2140221/2135112/1070
Vulvovaginal candidiasisInfections and infestations176/2140193/213587/1070

Baseline characteristics

Participants from the Randomized Blinded Phase Safety Analysis Set were analyzed.

Age, Categorical
Age, Categorical(Participants)Randomized Blinded Phase: LenacapavirRandomized Blinded Phase: F/TAFRandomized Blinded Phase: F/TDFTotal
<=18 years287256125668
Between 18 and 65 years185318799454677
>=65 years0000
Age, Continuous
Age, Continuous(years)Randomized Blinded Phase: LenacapavirRandomized Blinded Phase: F/TAFRandomized Blinded Phase: F/TDFTotal
Mean21 ± 2.221 ± 2.121 ± 2.121 ± 2.1
Sex: Female, Male
Sex: Female, Male(Participants)Randomized Blinded Phase: LenacapavirRandomized Blinded Phase: F/TAFRandomized Blinded Phase: F/TDFTotal
Female2140213510705345
Male0000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Randomized Blinded Phase: LenacapavirRandomized Blinded Phase: F/TAFRandomized Blinded Phase: F/TDFTotal
Hispanic or Latino0000
Not Hispanic or Latino2140213510705345
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Randomized Blinded Phase: LenacapavirRandomized Blinded Phase: F/TAFRandomized Blinded Phase: F/TDFTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American2137213410685339
White0000
More than one race3126
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(Participants)Randomized Blinded Phase: LenacapavirRandomized Blinded Phase: F/TAFRandomized Blinded Phase: F/TDFTotal
South Africa181117889094508
Uganda329347161837
08

Study locations

28 sites
  • Madibeng Centre for Research
    Brits, 2500, South Africa
  • Emavundleni Research Centre
    Cape Town, 7750, South Africa
  • Vuka Research Clinic
    Cape Town, 7784, South Africa
  • Desmond Tutu Health Foundation Clinical Trials Unit
    Cape Town, 7925, South Africa
  • Botha's Hill Clinical Research Site, HIV Prevention Research Unit
    Durban, 3660, South Africa
  • CAPRISA eThekwini Clinical Research Site
    Durban, 4001, South Africa
  • CAPRISA Vulindlela Clinical Research Site
    Durban, 4001, South Africa
  • MatCH Research Unit, Suite 1112, 11th Floor
    Durban, 4001, South Africa
  • Synergy Biomed Research Institute (SBRI)
    East London, South Africa
  • Setshaba Research Centre
    Gauteng, 152, South Africa
  • Wits Reproductive Health & HIV Institute (Wits RHI)
    Johannesburg, 2038, South Africa
  • The Aurum Institute: Gavin J Churchyard Legacy Centre, Klerksdorp Clinical Research Centre
    Klerksdorp, 2571, South Africa
  • Perinatal HIV Research Unit (PHRU) Soweto Kliptown
    Kliptown, 1809, South Africa
  • Phoenix Clinical Research Site, South African Medical Research Council, HIV and Other Infectious Disease Research Unit
    Kwa Zulu Natal, 4061, South Africa
  • Verulam Clinical Research Site, South African Medical Research Council, HIV and Other Infectious Disease Research Unit
    Kwa Zulu Natal, 4340, South Africa
  • Tongaat Clinical Research Site, South African Medical Research Council, HIV and Other Infectious Disease Research Unit
    Kwa Zulu Natal, 4400, South Africa
  • Chatsworth Clinical Research Site, South African Medical Research Council, HIV and Other Infectious Disease Research Unit
    Kwa Zulu Natal, South Africa
  • Qhakaza Mbokodo Research Clinic
    Ladysmith, 3370, South Africa
  • Africa Health Research Institute
    Mtubatuba, 3935, South Africa
  • The Aurum Institute: Pretoria Clinical Research Centre
    Pretoria, 0087, South Africa
  • The Aurum Institute: Rustenburg Clinical Research Centre
    Rustenburg, 299, South Africa
  • Desmond Tutu Health Foundation - Masiphumelele Research Office
    Sunnydale, 7705, South Africa
  • The Aurum Institute: Tembisa Clinical Research Centre
    Tembisa, 1632, South Africa
  • CAPRISA Umlazi Clinical Research Site
    Umlazi, 4066, South Africa
  • FPD-DTHF Ndevana Community Research Site
    Vincent, 5217, South Africa
  • Makerere-Kalangala Clinical Research site
    Kalangala, Uganda
  • AMBSO Masaka Clinical Research site
    Kyotera- Masaka Region, Uganda
  • Makerere University- John Hopkins University (MU-JHU) Mityana Research Site (MU-JHU) Care Ltd
    Mityana Town, Uganda
09

References and documents

Publications

  • Bekker LG, Das M, Abdool Karim Q, Ahmed K, Batting J, Brumskine W, Gill K, Harkoo I, Jaggernath M, Kigozi G, Kiwanuka N, Kotze P, Lebina L, Louw CE, Malahleha M, Manentsa M, Mansoor LE, Moodley D, Naicker V, Naidoo L, Naidoo M, Nair G, Ndlovu N, Palanee-Phillips T, Panchia R, Pillay S, Potloane D, Selepe P, Singh N, Singh Y, Spooner E, Ward AM, Zwane Z, Ebrahimi R, Zhao Y, Kintu A, Deaton C, Carter CC, Baeten JM, Matovu Kiweewa F; PURPOSE 1 Study Team. Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women. N Engl J Med. 2024 Oct 3;391(13):1179-1192. doi: 10.1056/NEJMoa2407001. Epub 2024 Jul 24. PubMed 39046157 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2021 to primary completion in May 2024, 32 months.

Results were first posted in Jun 2025, 1 year after primary completion.

Of 57 industry-sponsored phase 3 interventional studies under HIV Infections, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 30. This study's 32 months is above that.

Counting every sponsor, half of 101 studies reached it within 27 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2021
First posted
Aug 6, 2021
StartActual
Aug 30, 2021
Primary completionActual
May 27, 2024
CompletionEst.
Jan 2028
Results first posted
Jun 19, 2025
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers and verification date
1 update, last Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Minor edits only
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04994509
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Aug 6, 2021
Start date
Aug 30, 2021
Primary completion
May 27, 2024
Completion
Jan 2028 (estimated)
Results posted
Jun 19, 2025
Last update
Oct 16, 2026

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lenacapavir · Emtricitabine · Tenofovir alafenamide

Start the discussion